EC Number   |
Application |
Reference  |
|---|
    1.14.13.9 | molecular biology |
development of a transformant selection system for Tribolium castaneum on the basis of mutant rescue |
658826 |
| 1.14.13.9 | medicine |
enzyme is a therapeutical target for treatment of Huntigton disease |
659985 |
| 1.14.13.9 | medicine |
the enzyme is an attractive target for the treatment of ischemic stroke |
-, 676975 |
| 1.14.13.9 | molecular biology |
the wild-type enzyme gene can be used as a marker gene for visually screening transgenic silkworms |
687098 |
| 1.14.13.9 | molecular biology |
wild-type KMO gene can be used as a marker gene for visually screening transgenic silkworms |
-, 687098 |
| 1.14.13.9 | medicine |
T helper 17 cells preferentially express kynurenine 3-monooxygenase. Enzyme inhibition, either with a specific inhibitor or via siRNA-mediated silencing, markedly increases IL-17 productionin vitro, whereas IFN-gamma production by T helper 1 cells is unaffected. Inhibition of kynurenine 3-monooxygenase significantly exacerbates disease in a Th17-driven model of autoimmune gastritis |
724908 |
| 1.14.13.9 | analysis |
comprehensive panel of biochemical and cell-based assays that use liquid chromatography/tandem mass spectrometry to quantify unlabeled kynurenine and 3-hydroxykynurenine and application to measure kynurenine monooxygenase inhibition in cell and tissue extracts, as well as cellular assays |
725567 |
| 1.14.13.9 | medicine |
the enzyme is a potential drug target for treatment of neurodegenerative disorders such as Huntington's and Alzheimer's diseases |
742081 |
| 1.14.13.9 | pharmacology |
the enzyme is a potential drug target for treatment of neurodegenerative disorders such as Huntington's and Alzheimer's diseases |
742081 |
| 1.14.13.9 | pharmacology |
kynurenine represents a branch point of the kynurenine pathway, being converted into the neurotoxin 3-hydroxykynurenine via kynurenine monooxygenase, neuroprotectant kynurenic acid, and anthranilic acid. As a result of this branch point, kynurenine monooxygenase is an attractive drug target for several neurodegenerative and/or neuroinflammatory diseases, especially Huntington's, Alzheimer's, and Parkinson's diseases |
742349 |
